Management of unknown primary with neck node metastasis: Current evidence

Dr. Pooja Nandwani Patel
Associate Professor
Dept. of Radiation Oncology
GCRI, Ahmedabad
Introduction - Approach to Topic

• What is MUO – different terminologies

• How to diagnose

• How to treat

• Review of literature

• Take home message
Different terminologies

- CUP: Carcinoma of unknown primary
- PUO: Primary of unknown origin
- MUO: Metastases of unknown origin
- UKP: Unknown primary
Unknown primary

• A lymph node in the neck with malignant pathology without any obvious primary mucosal origin.

• Head and neck unknown primaries are generally squamous cell carcinomas

• Incidence: 5% of head and neck cancers
Levels of the Neck
Levels of the Neck

• Level I - This includes the submental and submandibular lymph nodes.
  – The **submental triangle** (sublevel IA) is bounded by the anterior belly of the **digastric muscles** (laterally) and the **hyoid** (inferiorly). The **submandibular triangle** (sublevel IB) is bounded by the body of the **mandible** (superiorly), the **stylohyoid** (posteriorly), and the anterior belly of the digastric (anteriorly).

• Level II - This includes lymph nodes of the upper jugular group and is divided into sublevels IIA and IIB.
  – Level II is bounded by the inferior border of the hyoid (inferiorly), the base of **skull** (superiorly), the **stylohyoid muscle** (anteriorly) and the posterior border of the SCM (posteriorly). Sublevel IIA nodes lie anterior to the SAN. Sublevel IIB nodes lie posterior to the SAN.

• Level III - This includes lymph nodes of the middle jugular group.
  – This level is bounded by the inferior border of the hyoid (superiorly) and the inferior border of the **cricoid** (inferiorly), the posterior border of the **sternohyoid** (anteriorly) and the posterior border of the SCM (posteriorly).

• Level IV - This includes lymph nodes of the lower jugular group.
  – This level is bounded by the inferior border of the cricoid (superiorly), the **clavicle** / **sternal** notch (inferiorly), the posterior border of the sternohyoid (anteriorly) and the posterior border of the SCM (posteriorly).

• Level V - This includes posterior compartment lymph nodes.
  – This compartment is bounded by the clavicle (inferiorly), the anterior border of the **trapezius** (posteriorly), the posterior border of the SCM (anteriorly). It is divided into sublevels VA (lying above a transverse plane marking the inferior border of the anterior cricoid arch) and VB (below the aforementioned plane).

• Level VI - This includes the anterior compartment lymph nodes.
  – This compartment is bounded by the common **carotid** arteries (laterally), the hyoid (superiorly), the **suprasternal notch** (inferiorly).
• 3-5% of presentation, 55-65 years
• 80-85% are tonsil and base of tongue
• Most commonly level II F/B III whereas I, IV and V are less frequent.
• Unilateral more common and B/L 10%
• Metastases in upper neck is mostly from head and neck – SCC, PD (Exception Adenocarcinoma - thyroid, parathyroid and parotid)
• From lower neck below clavicles other than from head and neck - Adenoca
Clinical Presentation

• Patients generally present with a painless, solitary neck mass, most often discovered by the patient.

• Masses are usually at least 3-5 cm

• Patients have usually gone through at least one course of antibiotics

• Benign masses are also often solitary and painless
Differential diagnosis

• Benign
  – Developmental (i.e., thyroglossal duct cyst, branchial cleft cysts or inclusion cysts)
  – Inflammatory (i.e., lymphadenitis, benign reactive hyperplasia, infected sebaceous cyst)
  – Benign Neoplasms (i.e., lipoma, fibroma, hemangioma, neurofibroma, parathyroid adenoma or goiter)
Differential diagnosis

• Malignant
  – Metastatic carcinoma, sarcoma or melanoma
  – Lymphoma, Leukemia
  – Carotid body tumor
  – Primary major salivary gland tumor
  – Thyroid cancer
  – Parathyroid cancer
  – Histiocytosis
  – Carcinoid
Relationship of Node Location to Likely Disease

• Nodes at certain levels more likely certain primaries

• **Upper neck nodes** are the most likely to be head and neck cancer
  – Subdigastric node may be virtually any head and neck primary, or a non-Hodgkin’s lymphoma
  – Submandibular node suggests oral cavity, lip, nasal vestibule or salivary gland primary
  – Submental nodes are uncommon
Relationship of Node Location to Likely Disease

• **Mid Neck**
  – Likely primaries include larynx, hypopharynx, and less commonly esophagus, disease below clavicles or lymphoma

• **Lower Neck and Supraclavicular Nodes**
  – Most often metastatic from chest or abdomen, possible esophagus or lymphoma.

• **Parotid lymph nodes**

  Parotid lymph nodes are more likely skin cancer than from a primary parotid tumor
### TABLE 9  N Staging for All Head and Neck Sites Except the Nasopharynx and Thyroid

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nx</td>
<td>Regional lymph nodes cannot be assessed</td>
</tr>
<tr>
<td>N0</td>
<td>No regional lymph node metastasis</td>
</tr>
<tr>
<td>N1</td>
<td>Metastasis in a single Ipsilateral lymph node, 3 cm or less in greatest dimension</td>
</tr>
<tr>
<td>N2</td>
<td>Metastasis in a single Ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple Ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension</td>
</tr>
<tr>
<td>N2a</td>
<td>Metastasis in a single Ipsilateral lymph node more than 3 cm but not more than 6 cm in greatest dimension</td>
</tr>
<tr>
<td>N2b</td>
<td>Metastasis in multiple Ipsilateral lymph nodes, none more than 6 cm in greatest dimension</td>
</tr>
<tr>
<td>N2c</td>
<td>Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension</td>
</tr>
<tr>
<td>N3</td>
<td>Metastasis in a lymph node more than 6 cm in greatest dimension</td>
</tr>
</tbody>
</table>
Diagnosis

Physical exam

• Soft, rubbery nodules suggest lymphoma and leukemia
• Hard, fixed masses suggest carcinoma
• Indirect examination of oral cavity and oropharynx with mirror and/or fiberoptic endoscopy
Diagnosis

Imaging

• CT followed by an MRI if inconclusive
• If there is still no imaging data for a primary, a PET may be ordered
  – In a meta-analysis of 16 studies looking at the role of PET in 302 patients with cervical node metastases where a primary has yet to be discovered through the work up, 25% of primaries are identified through PET. Previously unrecognized regional or distant metastases were identified in 27% of patients
Axial low-dose CT (a), PET (b), fused PET–CT (c) and maximal intensity projection views (d) showing focal FDG uptake on the right valleculae, confirmed on biopsies (patient 38).
Diagnosis

- Fine needle biopsy of LN
- Incisional or excisional biopsy before definitive treatment
  - neck recurrence
  - distant metastasis
  - wound necrosis
• SCC and UD- EBV and p16

• EBV in situ hybridization – Nasopharyngeal malignancy

• SCC Polymerase chain reaction – Oropharyngeal malignancy

• Treat accordingly
Diagnosis

- Staging surgical endoscopy – panendoscopy (triple endoscopy) – direct laryngoscopy to evaluate oropharynx, larynx and hypopharynx, nasopharyngoscopy and upper esophagoscopy
Diagnosis

Screening Tonsillectomy

• If a primary site has not been discovered by this point, an ipsilateral screening tonsillectomy may be performed
  – This is of greatest benefit in patients with subdigastric, submandibular or midjugulocarotid lymph nodes
  – In a study of 87 patients with unknown primaries, 26% were discovered to have a tonsillar primary after tonsillectomy

  – Literature for bilateral tonsillectomy not convincing (no chance of missing contralateral tonsil and greater symmetry on PE after B/L tonsillectomy
Treatment

• Treat as aggressive disease

• Treat based on staging
• N1- neck dissection OR radiation
• N2, N3- combined neck dissection AND radiation
Basic guidelines

cN1: Options include radical neck dissection alone, neck dissection followed by adjuvant radiotherapy, or radiotherapy alone. Modified radical dissection likely confers similar survival as radical with appropriate adjuvant therapy, when final pathology reveals >N1 disease.\textsuperscript{11}

Clear indications for adjuvant radiotherapy (+/- chemotherapy) after neck dissection include:
- ≥N2 disease
- ECE
- positive margin
- previous neck violation

ECE and positive margins will warrant the addition of chemotherapy to PORT unless otherwise contraindicated.

≥cN2: Combined chemo + radiation therapy is recommended. Surgical management is an option though not preferred upfront. Adjuvant radiotherapy improves locoregional control. For very large nodes, consideration can be made for neck dissection first to remove bulk of disease, followed by adjuvant radiotherapy or chemoradiation.
Example RT prescription dosing is as follows:
- 66-70Gy to gross nodal disease,
- 60-63Gy to high risk nodal levels and likely mucosal primary sites
- 54-56Gy to elective nodal levels

Persistent or progressive nodal disease after radiotherapy should warrant surgical consultation for salvage neck dissection.

M1: Patients with metastatic disease should be referred to medical oncology for discussion of systemic therapy. Palliative radiotherapy for symptom control may be indicated or best supportive care.
• **Poorly Differentiated**

• Most frequent site is pharynx especially NP

• RT to neck and Waldeyer’s ring including NP

• Neck dissection for residual

• **Adenocarcinoma**

• Node at level I-III could be salivary gland tumor

• Excision biopsy indicated and if clinical and pathological cannot find primary then consensus on neck dissection (I-V) including parotidectomy if indicated followed by RT
**NCCN Guidelines Version 1.2015**

**Occult Primary**

**PRESENTATION**
- H&P\(^{a,b}\)
- Complete head and neck exam with attention to skin; palpation of the oropharynx; mirror and fiberoptic examination as clinically indicated to examine nasopharynx, oropharynx, hypopharynx, and larynx

**PATHOLOGY**
- Squamous cell carcinoma, adenocarcinoma, and anaplastic/undifferentiated epithelial tumors\(^d\)
  - Fine-needle aspiration (FNA)\(^c\)
  - Lymphoma
  - Thyroid
    - See NCCN Guidelines for Non-Hodgkin's Lymphomas
  - Melanoma
    - See NCCN Guidelines for Melanoma
      - Skin exam, note regressing lesions
      - See Workup for Mucosal Melanoma (MM-1)

**WORKUP**
- Chest imaging
- CT with contrast or MRI with gadolinium (skull base through thoracic inlet)
- PET/CT scan as indicated (before EUA)
- HPV, Epstein-Barr virus (EBV) testing suggested for squamous cell or undifferentiated histology\(^e\)
- Thyroglobulin, calcitonin, PAX8, and/or TTF staining for adenocarcinoma and anaplastic/undifferentiated tumors

**Primary found**
- Treat as appropriate
  - See Guidelines Index

**Primary not found\(^f\)**
- See Workup and Treatment (OC-2)
**NCCN Guidelines Version 1.2015**

**Occult Primary**

**Pathologic Workup Findings**

**Node level I, II, III, upper V**
- EUA
- Palpation and inspection
- Biopsy of areas of clinical concern and tonsillectomy ± lingual tonsillectomy
- Direct laryngoscopy and nasopharynx survey

**Node level IV, lower V**
- EUA including direct laryngoscopy, esophagoscopy
- Chest/abdominal/pelvic CT (or PET/CT if not previously performed)

**Primary found**

- Adenocarcinoma of neck node, thyroglobulin negative, calcitonin negative
  - Levels I-III
  - Levels IV, V

- Poorly differentiated or nonkeratinizing squamous cell or not otherwise specified (NOS) or anaplastic (not thyroid) of neck node or squamous cell carcinoma of neck node

**Definitive Treatment**

- Treat as appropriate
  (See Guidelines Index)

- Neck dissection + parotidectomy, if indicated
  - RT¹ to neck ± parotid bed

- Evaluate for infraclavicular primary
  - Neck dissection, if indicated

- See Definitive Treatment (OCC-3)
**HISTOLOGY**

- Poorly differentiated or nonkeratinizing squamous cell or NOS or anaplastic (not thyroid) or Squamous cell carcinoma

**DEFINITIVE TREATMENT**

- Surgery$^h$ (preferred for < N2 disease)
  - or
  - RT$^i$ for < N2 (category 2B)
    - or
    - Systemic therapy/RT$^{ij}$ for ≥ N2 (category 2B)
      - or
      - Induction chemotherapy$^{jk}$ (category 3) followed by systemic therapy/RT$^{ij}$ or RT$^i$

  $\rightarrow$ Neck dissection$^h$

  $\rightarrow$ See OCC-4

- Complete clinical response
  $\rightarrow$ Post-treatment evaluation$^i$

  $-$ Negative $\rightarrow$ Observe

  $-$ Positive $\rightarrow$ Neck dissection$^h$

- Residual tumor in neck
  $\rightarrow$ Neck dissection$^h$
NCCN Guidelines Version 1.2015
Occult Primary

**N1 without extracapsular spread**
- **RT\(^1\)** (Target volume determined by tumor size, nodal station, and HPV\(^m\) and EBV status)\(^e\)
or
  - Observation\(^n\)

**N2, N3 without extracapsular spread**
- **RT\(^1\)** (Target volume determined by tumor size, nodal station, and HPV\(^n\) and EBV status)\(^e\)
or
  - Consider systemic therapy/RT\(^{ij}\) (category 2B)

**Post neck dissection**
- **Extracapsular spread**
  - Systemic therapy/RT\(^{ij}\) (category 1)
or
  - **RT\(^1\)** (Target volume determined by tumor size, nodal station, and HPV\(^m\) and EBV status)\(^e\)

**Follow-up**
(See FOLL-A)

- **Recurrent or Persistent disease**
  (See ADV-3)
PRINCIPLES OF RADIATION THERAPY

DEFINITIVE
RT Alone
- PTV
  - High risk: Involved lymph nodes (this includes possible local subclinical infiltration at the high-risk level lymph node(s))
    - Fractionation:
      - 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday–Friday in 6–7 weeks
      - Mucosal dosing: 50–66 Gy (2.0 Gy/fraction) to putative mucosal sites, depending on field size. Consider higher dose to 60–66 Gy to particularly suspicious areas
  - Low to intermediate risk: Sites of suspected subclinical spread
    - 44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction)

CONCURRENT CHEMORADIATION
- PTV
  - High risk: typically 70 Gy (2.0 Gy/fraction)
  - Mucosal dosing: 50–60 Gy (2.0 Gy/fraction) to putative mucosal primary sites, depending on field size and use of chemotherapy. Consider higher dose to 60–66 Gy to particularly suspicious areas
  - Low to intermediate risk: 44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction)

Either IMRT or 3-D conformal RT is recommended when targeting the oropharynx to minimize the dose to critical structures, especially the parotid glands.
PRINCIPLES OF RADIATION THERAPY\textsuperscript{1,2}

POSTOPERATIVE:
RT
- Preferred interval between resection and postoperative RT is \textless 6 weeks
- PTV
  - High risk: Adverse features such as extracapsular spread (See OCC-4)
    - Mucosal dose: 50–66 Gy (2.0 Gy/fraction) to putative mucosal sites, depending on field size.
      - Consider higher dose to 60–66 Gy to particularly suspicious areas
  - Low to intermediate risk: Sites of suspected subclinical spread
    - 44–50 Gy (2.0 Gy/fraction) to 54-63 Gy (1.6–1.8 Gy/fraction)\textsuperscript{4}

POSTOPERATIVE CHEMORADIATION
- Concurrent single-agent cisplatin at 100 mg/m\textsuperscript{2} every 3 weeks is recommended\textsuperscript{7-10}

Either IMRT or 3-D conformal RT is recommended when targeting the oropharynx to minimize the dose to critical structures, especially the parotid glands.
Part of the purpose of using IMRT is to decrease dose to the parotid, in order to decrease the grade of xerostomia and improve dose homogeneity.

- Bhide, S et al. Intensity modulated radiotherapy improves target coverage and parotid gland sparing when delivering total mucosal irradiation in patients with squamous cell carcinoma of head and neck of unknown primary site. 2007; 32(3):188-95

- Can also keep dose off of the larynx
Radiation

- Ipsilateral neck vs. bilateral neck, Bilateral favored
- Some studies show increase risk of neck disease or emergence of primary with ipsilateral treatment compared to bilateral without overall survival being affected
- Alternate studies show extensive radiation of mucosa and bilateral neck improve survival compared to ipsilateral neck radiation
  - Study of 352 patients with squamous cell or undifferentiated cancer of the cervical lymph nodes with no evident primary, the patients who received ipsilateral neck radiation compared to those receiving bilateral had a 1.9 relative risk of recurrence in the head and neck and lower 5 year disease free survival
Largest experience with primary RT – Danish Society of Head and Neck Oncology over a 20 year period

- 352 patients with CUP
- 277 were managed with bilateral neck irradiation and elective irradiation of sites in the nasopharynx, hypopharynx and larynx
- 26 received ipsilateral nodal irradiation only
- Patients treated with ipsilateral neck radiation compared to those receiving bilateral neck radiation had a 1.9-fold higher risk of recurrence in the head or neck (51 versus 27 percent, \( p = 0.05 \))
- Ipsilateral nodal irradiation also had a trend toward lower five year disease-specific survival (28 versus 45 percent).

Grau et al., Radiotherapy and Oncology. 2000 (55)
Radiation by Node location

• Upper nodes
  – Naso-, oro- and hypopharynx and supraglottic larynx. Oral cavity not included
• Junctional or lateral retropharyngeal node
  – Naso- and oropharynx
• Submandibular- solitary node
  – Neck only because of the major morbidity of irradiating the entire oral cavity
• Midjugular
  – Oro-, hypopharynx and supraglottic larynx
• Supraclavicular
  – Large portal to include apex of axilla
Metastatic Cervical LNs

- Cervical node metastases of squamous cell carcinoma from occult primary constitute about 2-5% of all patients with CUP

- Mets in upper & mid neck
  - attributed to H&N cancers

- Lower neck (SCF)
  - associated with $1^0$ below the clavicles e.g. lung or GI tract

---

Fig. 2 The cross-hatched zones show the usual sites for metastatic lesions in the neck from primary tumours originating in the structures indicated. (Adapted from Dsugaard 1994.)
Results

• Emergence rate of primary is 25%
• Medial nodal recurrence rate  35%
• 5 year overall survival rate 66%
• Estimated actuarial risk of emergence of head and neck primary after extensive irradiation reaches 20% at 10 years.
• Median time to occurrence of subsequent primaries is about 21 months
Complications of Radiation Therapy

- Most common complication is xerostomia (dry mouth due to decreased saliva production)
- Fatigue
- Mucositis
- Altered taste sensations
- Red and irritated skin
- Occasional nausea
- Esophageal stricture
Chemotherapy

- Platinum-based chemotherapy in combination with radiation recommended for N3 patients by European Society of Medical Oncology (ESMO)
- Consider concurrent chemo/RT with supraclavicular LN or undifferentiated tumors, though no strong data to support
- Chemo/ RT is an option for palliation, unresectable local disease, distant metastatic spread
Follow up

- TFT should be monitored if the patient received radiation to the lower neck since up to 30% of patients may develop subclinical or overt radiation induced hypothyroidism.
- Clinical and fibrescopic check every two months in the first year, every four months for second an third every year then every six months.
- PET once a year, additional examination at discretion.
Recurrence

• Comparing subsequent mucosal primary lesions in patients with unknown primaries to head and neck cancer with a known primary site shows the incidence of a subsequent mucosal recurrence was similar for both groups.
Recurrence

- Location (primary site, new primary site, neck or distant), the histology, time since initial diagnosis and prior therapies.
- Surgical management is favored for patients previously treated with radiotherapy, and likewise those previously having undergone surgery alone should be considered for radiotherapy (+/- chemotherapy).
- Some patients - for repeat radiotherapy even to high doses.
- Small localized recurrences may be managed surgically in some cases.
- Recurrence at the base of skull or other difficult-to-access locations can benefit from external consultation at centers equipped with gamma knife or SBRT technologies.
- Other options include palliative radiotherapy or best supportive care.
Prognosis

• The best indicator of prognosis is N stage at presentation
• Also, the presence of extracapsular extension is associated with a poorer prognosis
• Prognosis is similar between patients with a known vs. an unknown primary with the same nodal stage.
Future Research

• Phase III Randomized Study of Selective Irradiation Versus Extensive Irradiation in Patients With Cervical Lymph Node Metastases of Squamous Cell Carcinoma From an Unknown Primary- Opened 2002, now closed awaiting for results

• EORTC-24001, EORTC-22005, DAHANCA-EORTC-24001, CAN-NCIC-EORTC-24001, RTOG-EORTC-24001, NCT00047125
• Depends on whether source is found during workup
• If primary site identified treat accordingly, ND followed by PORT to neck and mucosal sites
• Distinct advantages for different options – Surgery/RT/CT+RT
• Mucosal irradiation decrease primary emergence but at cost
• Tailoring of therapy according to HPV, EBV, Nodal level, history prevent unwarranted toxicity
<table>
<thead>
<tr>
<th>Comprehensive neck dissection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radical neck dissection</td>
</tr>
<tr>
<td>Modified radical neck dissection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Selective neck dissection</th>
</tr>
</thead>
<tbody>
<tr>
<td>One or more of the lymphatic groups normally removed in the radical neck dissection is preserved. The lymph node groups removed are based on patterns of metastases which are predictable for each site of the disease.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Extended neck dissection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional lymph node groups or non-lymphatic structures are removed.</td>
</tr>
</tbody>
</table>
• Although in politics you cover the known, in medicine you uncover the unknown